Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BGeorge Lau, N. Pluck|New England Journal of Medicine|2005Cited by 1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Kabir Mody et al.|NEJM Evidence|2022Cited by 1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
Hepatocellular Carcinoma (HCC)Péter Ferenci, Anton Le Mair, Michael Fried et al.|Journal of Clinical Gastroenterology|2010Cited by 322
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)Shiv Kumar Sarin, Ashok Choudhury, George Lau et al.|Hepatology International|2020Cited by 295